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INTRODUCTION: 
A Microsponges Delivery System (MDS) is “Patented, 
highly cross-linked, porous, polymeric microspheres, 
polymeric system consisting of porous microspheres that 
can entrap wide range of actives and then release them 
into the skin over a time and in response to trigger”. 10-
25 microns in diameter.1 Micro-sponge polymers possess 
the versatility to load a wide range of actives providing 
the benefits of enhanced product efficacy, mildness, 
tolerability, and extended wear to a wide range of skin 
therapies. Several predictable and reliable systems were 
developed for systemic drugs under the heading of 
transdermal delivery system (TDS) using the skin as 
portal of entry. It has improved the efficacy and safety of 
many drugs. But TDS is not practical for delivery of 
materials whose final target is skin itself. Thus the need 
exists for system to maximize amount of time that an 
active ingredient is present either on skin surface or 
within the epidermis, while minimizing its transdermal 
penetration in the body .2, 3, 4 
Microsponges are polymeric delivery systems composed 
of porous microspheres. They are tiny sponge-like 
spherical particles with a large porous surface. Moreover, 
they may enhance stability, reduce side effects and 
modify drug release favorably. Microsponge technology 
has many favourable characteristics, which make it a 
versatile drug delivery vehicle. Microsponge Systems are 
based on microscopic, polymer-based microspheres that 
can suspend or entrap a wide variety of substances, and 
can then be incorporated into a formulated product such 
as a gel, cream, liquid or powder. MDS can provide 
increased efficacy for topically active agents with 
enhanced safety, extended product stability and 
improved aesthetic properties in an efficient manner. 5, 6, 7 
The microsponge technology was developed by Won in 
1987, and the original patents were assigned to 
Advanced Polymer Systems, Inc. This company 
developed a large number of variations of the procedures 
and those are applied to the cosmetic as well as over-the- 
counter (OTC) and prescription pharmaceutical products. 
At the current time, this interesting technology has been 
licensed to Cardinal Health, Inc., for use in topical 
products. The scanning electron microscopy of the 
microsponge particle reveals that its internal structure as 
the “bag of marbles”.  
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ABSTRACT: 
The drug delivery technology landscape has become highly competitive and rapidly evolving. More and more developments in 
delivery systems are being integrated to optimize the efficacy and cost-effectiveness of the therapy. Peptides, proteins and 
DNA-based therapeutics cannot be effectively delivered by conventional means. A Microsponges delivery system is a highly 
cross-linked, porous, polymeric microsphere, polymeric system consisting of porous microspheres that can entrap and release 
them into the skin over a long period of time. This delivery system provides extended release with reduced irritation, better 
tolerance, improved thermal, physical and chemical stability. The main goal of any drug delivery system is to achieve desired 
concentration of the drug in blood or tissue, which is therapeutically effective and non-toxic for a prolonged period In the 
present study various methods for preparation of microsponges drug delivery system are studied. Various advantages are also 
given which shows the importance of this method for the delivery of drugs over the other drug delivery system.  More and 
more developments in delivery systems are being integrated to optimize the efficacy and cost-effectiveness of the therapy. 
Microsponge technology offers entrapment of ingredients and is believed to contribute towards reduced side effects, improved 
stability, increased elegance, and enhanced formulation flexibility. In addition, numerous studies have confirmed that 
microsponge systems are non-irritating, nonmutagenic, non-allergenic, and non-toxic. Microsponges delivery technology is 
being used currently in cosmetics, over-the-counter (OTC) skin care, sunscreens and prescription products. One of the best 
feature of microsponge is it is self-sterilizing. This review is focused on method of preparation, characterization and application 
of microsponge. 
Keywords: Microsponge, Control relaease, Target release, topical formulation, oral administration 
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The porosity is due to the interstitial spaces between the 
marbles. The interstitial pores can entrap many wide 
range of active ingredients such as emollients, 
fragrances, essential oils, sunscreens, anti-infective and 
anti-inflammatory agents. 8, 9 
Benefits of microsponge drug delivery systems: 
10, 11, 12
 
 Enhanced product performance. 
 Extended release. 
 Diminish irritation and hence enhanced patient 
Compliance. 
 Improved product elegancy. 
 Improved oil control as it can absorb oil up to 6 
times its weight without drying. 
 Allows for novel product forms.  
 Improves efficacy in treatment.  
 Cure or control confirm more promptly.  
 Improve control of condition.  
 Improve bioavailability of same drugs  
 Flexibility to develop novel product forms. 
 Non-irritating, non-mutagenic, non-allergenic and 
non-toxic 
 Improves stability, thermal, physical and chemical 
stability  
 Allows incorporation of immiscible products.  
 Improves material processing eg. liquid can be 
converted to powders 
Limitations: 
The preparation methods usually use organic solvents as 
porogens, which pose an environmental hazard, as some 
may be highly inflammable, posing a safety hazard. In 
some cases, the traces of residual monomers have been 
observed, which may be toxic and hazardous to health.  
Potential features of microsponge drug delivery 
system: 
13, 14, 15, 16
 
 Shows tolerable stability over pH ranging from 1 to 
11 and at high temperatures (up to130°C). 
  Reveal good compatibility with various vehicles 
and ingredients. 
 High entrapment efficiency up to 50 to 60%. 
 Are characterized by free flowing properties. 
 The average pore size of microsponges is small 
(0.25 μm) in a way to prevent the penetration of 
bacteria, thus they do not need sterilization or 
addition of preservatives. 
 Can absorb oil up to 6 times their weight without 
drying. 
Characteristics of moieties that is entrapped in 
microsponges:
17, 18 
 Either fully miscible in monomer or capable of 
being made miscible by addition of small amount of 
a water immiscible solvent.  
 Stable in contact with polymerization catalyst and 
conditions of polymerization.  
 The spherical structure of microsponges should not 
collapse. 
 Active ingredients that are entrapped in microsponge 
can then be incorporated into many products such as 
creams, gels, powders, lotions and soaps.  
 The solubility of actives in the vehicle must be 
limited to avoid cosmetic problems; not more than 
10 to 12% w/w microsponges must be incorporated 
into the vehicle. Otherwise the vehicle will deplete 
the microsponges before the application. 
 Water immiscible or at most only slightly soluble.  
 Inert to monomers.  
 Payload and polymer design of the microsponges for 
the active must be optimized for required release 
rate for given period of time. 
METHOD OF PREPARATION OF 
MICROSPONGE DRUG DELIVERY SYSTEM: 
A Porogen drug neither hinders the polymerization 
process nor become activated by it and also it is stable to 
free radicals is entrapped with one-step process (liquid-
liquid suspension polymerization). Microsponges are 
suitably prepared by the following methods:  
1. Liquid-liquid suspension polymerization: 
19, 20, 21 
The porous microspheres are prepared by suspension 
polymerization method in liquid-liquid systems. In this 
method the monomers which are immiscible are first 
dissolved along with active ingredients in a suitable 
solvent monomer and are then dispersed in the aqueous 
phases which consist of additives like surfactant, 
suspending agents to facilitate formation of suspension. 
The polymerization is then activated by increasing 
temperature or irradiation or by addition of catalyst. The 
polymerization process continues the formation of a 
reservoir type of system with spherical structure. After 
the polymerization process the solvent is removed 
leaving the spherical structured porous microspheres, 
i.e., microsponges 
The various steps involved in the preparation of 
microsponges are summarized as follows:  
Step 1: Selection of monomer as well as combination of 
monomers.  
Step 2: Formation of chain monomers as polymerization 
starts.  
Step 3: Formations of ladders as a result of cross-linking 
between chain monomers.  
Step 4: Folding of monomer ladder to form spherical 
particles.  
Step 5: Agglomeration of microspheres leads to the 
production of bunches of microspheres.  
Step 6: Binding of bunches to produce microsponges.  
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Figure 1: Microsponges preparations by liquid-liquid 
Suspension polymerization 
 
2. Quasi-Emulsion Solvent Diffusion Method: 22, 23, 24 
Porous microspheres (microsponges) were also prepared 
by a quasi-emulsion solvent diffusion method (two-step 
process) using an internal phase containing polymer such 
as Eudragit RS 100 which is dissolved in ethyl alcohol. 
Then, the drug is slowly added to the polymer solution 
and dissolved under ultrasonication at 35oC and 
plasticizer such as triethylcitrate (TEC) was added in 
order to aid the plasticity. The inner phase is then poured 
into external phase containing polyvinyl alcohol and 
distilled water with continuous stirring for 2 hours11. 
Then, the mixture was filtered to separate the 
microsponges. The product (microsponges) was washed 
and dried in an air heated oven at 40°C for 12 hrs.
 
 
 
Figure 2: Preparation of microsponges by quasi emulsion solvent diffusion method 
 
RELEASE MECHANISM OF MICROSPONGE: 
25, 
26
 
As the microsponge particles have an open structure 
(they do not have a continuous membrane surrounding 
them), the active is free to move in and out from the 
particles and into the vehicle until equilibrium is reached, 
when the vehicle becomes saturated. Once the finished 
product is applied to the skin, the active that is already in 
the vehicle will be absorbed into the skin, depleting the 
vehicle, which will become unsaturated, therefore, 
disturbing the equilibrium. This will start a flow of the 
active from the microsponge particle into the vehicle, 
and from it to the skin, until the vehicle is either dried or 
absorbed. Even after that the microsponge particles 
retained on the surface of the stratum corneum will 
continue to gradually release the active to the skin, 
providing prolonged release over time. This proposed 
mechanism of action highlights the importance of 
formulating vehicles for use with microsponge 
entrapments. If the active is too soluble in the desired 
vehicle during compounding of the finished products, the 
products will not provide the desired benefits of gradual 
release. 
Accelerated or Triggered by following mechanism: 
 Pressure triggered systems 
 Temperature triggered systems 
 pH triggered systems 
 Solubility triggered system 
FACTORS AFFECTING DRUG RELEASE FROM 
MICROSPONGE DELIVERY SYSTEM:
 19
 
 Physical properties of Microsponge system like pore 
diameter, pore volume, resiliency etc. Properties of 
vehicle in which the microsponges are finally 
dispersed.  
 Pressure Rubbing/ pressure applied can release 
active ingredient from microsponges onto skin.  
 Temperature change some entrapped actives can be 
too viscous at room temperature to flow 
spontaneously from microsponges onto the skin. 
Increased in skin temperature can result in an 
increased flow rate and hence release.  
 Solubility Microsponges loaded with water-soluble 
ingredients like antiperspirants and antiseptics will 
release the ingredient in the presence of water. The 
release can also be activated by diffusion taking into 
consideration the partition coefficient of the 
ingredient between the microsponges and the outside 
system. 
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PHYSICAL CHARACTERIZATION OF 
MICROSPONGE DRUG DELIVERY SYSTEM: 
Particle size and shape: 
27
 
Free-flowing powders with fine aesthetic attributes are 
possible to obtain by controlling the size of particles 
during polymerization. Particle size analysis of loaded 
and unloaded microsponges can be performed by laser 
light diffractometry or any other suitable method. The 
values (d50) can be expressed for all formulations as 
mean size range. Cumulative percentage drug release 
from microsponges of different particle size will be 
plotted against time to study effect of particle size on 
drug release. Particle larger than 30 μm can impart gritty 
feeling and hence particles of sizes between10 and 25 
μm are preferred to use in final topical formulation. 
The most widely used procedures to visualize 
microparticles are conventional light microscopy (LM) 
and scanning electron microscopy (SEM). Both can be 
used to determine the shape and outer structure of 
microparticles. LM provides a control over coating 
parameters in case of double walled microparticles. 
Conflocal fluorescence microscopy is used for the 
structure characterization of multiple walled 
microparticles. Laser light scattering and multi size 
coulter counter other than instrumental methods, which 
can be used for the characterization of size, shape and 
morphology of the microparticles (microsponges). 
Morphology and surface topography of 
microsponges: 
28
 
Prepared microsponges can be coated with gold–
palladium under an argon atmosphere at room 
temperature and then the surface morphology of the 
microsponges can be studied by scanning electron 
microscopy (SEM). SEM of a fractured microsponge 
particle can also be taken to illustrate its ultra-structure. 
Determination of loading efficiency and production 
yield: 
29 
The loading efficiency (%) of the microsponges can be 
calculated according to the following Equation:  
 
 
The production yield of the micro particles can be 
determined by calculating accurately the initial weight of 
the raw materials and the last weight of the microsponge 
obtained.  
 
 
Compatibility studies: 
30 
Compatibility of drug with reaction adjuncts can be 
studied by thin layer chromatography (TLC) and Fourier 
Transform Infra-red spectroscopy (FT-IR).  Effect of 
polymerization on crystallinity of the drug can be studied 
by powder X-ray diffraction (XRD) and Differential 
Scanning Colorimetry (DSC). For DSC approximately 5 
mg samples can be accurately weighed into aluminum 
pans and sealed and can be run at a heating rate of 15 
C/min over a temperature range 25–430 C in atmosphere 
of nitrogen. 
Resiliency (viscoelastic properties): 
31 
Resiliency (viscoelastic properties) of microsponges can 
be modified to produce beadlets that is softer or firmer 
according to the needs of the final formulation.  
Increased cross-linking tends to slow down the rate of 
release. 
Drug release kinetics: 
32 
The dissolution profile of each formulation have been 
subjected to various models such as Zero order kinetics 
(percentage drug release against time), First order 
kinetics (log percentage drug unreleased against time), 
Higuchi (percentage drug released against square root of 
time) and Korsemeyer-Peppas (log percent drug released 
against log of time) were applied to assess the kinetics of 
drug release from prepared microsponges. 
Dissolution tests: 
Dissolution release rate of microsponges can be studied 
by use of dissolution apparatus USP XXIII with a 
modified basket consisted of 5μm stainless steel mesh. 
The dissolution medium is selected while considering 
solubility of actives to ensure sink conditions. At various 
intervals the samples from the dissolution medium was 
analysed by suitable analytical methods. 
Determination of true density: 
33 
The true density of micro particles and BPO was 
measured using an ultra-pycnometer under helium gas 
and was calculated from a mean of repeated 
determinations. 
Characterization of pore structure: 
34
  
Pore volume and diameter are vital in controlling the 
intensity and duration of effectiveness of the active 
ingredient. Pore diameter also affects the migration of 
active ingredients from microsponges into the vehicle in 
which the material is dispersed. Mercury intrusion 
porosimetry can be employed to study effect of pore 
diameter and volume with rate of drug release from 
microsponges. Porosity parameters of microsponges such 
as intrusion-extrusion isotherms pore size distribution, 
total pore surface area, average pore diameters, shape 
and morphology of the pores, bulk and apparent density 
can be determined by using mercury intrusion 
porosimetry.  
WORK DONE ON MICROSPONGES DRUG 
DELIVERY SYSTEM: 
Karthika et al fabricated microsponges drug delivery 
system using the drug Lornoxicam. They prepared the 
formulation using Quasi emulsion solvent diffusion 
method Eudragit RS 100. The effects of drug to polymer 
ratios on physical characteristics of the microsponges 
were investigated. Lornoxicam is a Non-steroidal anti-
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inflammatory drug used for the treatment of various 
inflammatory diseases. This study presents a new 
approach based on microsponge drug delivery system. 35 
John et al formulated microsponges drug delivery system 
using anti-inflammatory gels of Flucinolone Acetonide 
Entrapped in Eudragit. They prepared the formulation 
using Quasi emulsion solvent diffusion method Eudragit 
RS 100. The main aim to produce Flucinolone Acetonide 
microsponges was to control the release of drug to the 
skin. 36 
Vikas et al prepared microsponges drug delivery system 
using the dicyclomine. They prepared the formulation 
using Quasi emulsion solvent diffusion method Eudragit 
RS 100. Process parameters were modulated to optimize 
the formulation. Shape and surface morphology of the 
microsponges were examined using scanning electron 
microscopy. 37 
Saboji et al formulated microsponges drug delivery 
system using the drug ketoconazole. They prepared the 
formulation using Quasi emulsion solvent diffusion 
method Eudragit RS 100.The The physical 
characterization showed that microsponge formulation 
MS IV and MS VI showed a better loading efficiency 
and production yield. The microsponge ketoconazole gel 
formulations showed an appropriate drug release profile 
and also bring remarkable decrease on gel application for 
fungal treatment. 38 
Ramani Gade et al design and development of 
Hydroxyzine hydrochloride controlled release tablets 
based on microsponges. These are prepared by oil in oil 
emulsion solvent diffusion method using acetone as 
dispersing solvent. Hydroxyzine hydrochloride is an anti-
histaminic drug used in the treatment of urticaria and 
pruritus. Thickness, hardness, friability, % drug content 
and invitro release studies were done on microsponge 
tablets. 39 
Mahajan et al formulated microsponges drug delivery 
system using the drug Indomethacin. They prepared the 
formulation using Quasi emulsion solvent diffusion 
method Eudragit RS 100, pH independent release 
retardant polymer and polymer, stabilizer by changing 
the drug polymer ration. They evaluated micromeritic 
properties, drug content, encapsulation efficiency and 
particle size. They did the characterization for 
formulation by DSC, X-Ray diffraction and SEM.40 
PHARMACEUTICAL UTILIZATION OF 
MICROSPONGES:  
Microsponge delivery systems are used to enhance the 
safety, effectiveness and aesthetic quality of topical 
prescription, over-the-counter and personal care 
products. Microsponges can be used in variety of 
applications. It is used mostly for topical and recently for 
oral administration. Several patents have reported that it 
can be used as an excipients due to its high loading 
capacity and sustained release ability. 
Long lasting Coloured Cosmetics: 41, 42 
Colours entrapped in microsponges may be used in a 
variety of coloured cosmetic products such as rouge or 
lipsticks to make them long lasting. As stated above, 
microsponges help in uniform spreading and improving 
covering power. Thus, colored cosmetics formulated 
with microsponges would be highly elegant.  
For topical administration: 
43, 44
 
A single microsponge is as tiny as a particle of talcum 
powder, measuring less than one-thousandth of an inch 
in diameter. Like a true sponge, each microsphere 
consists of a myriad of interconnecting voids within a 
non-collapsible structure that can accept a wide variety 
of substances. The outer surface is typically porous, 
allowing the controlled flow of substances into and out 
of the sphere. Several primary characteristics, or 
parameters, of the microsponge system can be defined 
during the production phase to obtain spheres that are 
tailored to specific product applications and vehicle 
compatibility. Microsponge systems are made of 
biologically inert polymers. Extensive safety studies 
have demonstrated that the polymers are non-irritating, 
non- mutagenic, non-allergenic, non-toxic and non-
biodegradable. As a result, the human body cannot 
convert them into other substances or break them down. 
Although they are microscopic in size, these systems are 
too large to pass through the stratum corneum when 
incorporated into topical products. Benzoyl peroxide is 
commonly used in topical formulations for the treatment 
of acne, with skin irritation as a common side effect. 
For oral administration: 
45
 
In oral applications, the microsponge system has been 
shown to increase the rate of solubilisation of poorly 
water soluble drugs by entrapping such drugs in the 
microsponge system's pores. As these pores are very 
small, the drug is in effect reduced to microscopic 
particles and the significant increase in the surface area 
thus greatly increases the rate of solubilisation. 
Controlled oral delivery of ibuprofen microsponges is 
achieved with an acrylic polymer, Eudragit RS, by 
changing their intraparticle density. Sustained release 
formulation of chlorpheniramine maleate, using powder-
coated microsponges, is prepared by the dry impact 
blending method, for oral drug delivery.  
For Bone and Tissue Engineering: 
46, 47
 
Compounds were obtained by mixing pre polymerized 
powders of polymethyl methacrylate and liquid methyl 
methacrylate monomer with two aqueous dispersions of 
tricalcium phosphate grains and calcium deficient 
hydroxyapatite powders. The final composites appeared 
to be porous and acted as microsponges. Basic fibroblast 
growth factor (bFGF) incorporated in a collagen sponge 
sheet was sustained released in the mouse sub-cutis 
according to the biodegradation of the sponge matrix, 
and exhibited local angiogenic activity in a dose-
dependent manner.  
RECENT DEVELOPMENTS IN MICROSPONGE 
DRUG DELIVERY SYSTEM: 
48
 
Various advances were made by modifying the methods 
to form Nanosponges, nanoferrosponges and porous 
micro beads. β - CD nanosponges were also developed 
that can be used for hydrophobic as well as hydrophilic 
drugs, in contrast to polymeric micro or nanosponges. 
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These advanced systems were studied for oral 
administration of dexamethasone, Flurbiprofen, 
doxorubicin hydrochloride, itraconazole and serum 
albumin as model drug. These nanosponges were 
developed by cross- linking the β CD molecule by 
reacting the β-CD with biphenyl carbonate. Some 
researchers also observed the nanosponges as good 
carrier for the delivery of gases. Researchers also 
observed that incorporating a cytotoxic in a nanosponge 
carrier system can increase the potency of the drug 
suggesting that these carriers can be potentially used for 
targeting the cancerous cells. 
CONCLUSION 
The microsponge delivery technology of controlled 
release system in which active pharmaceutical ingredient 
is loaded in the macro porous beads and initiates 
reduction in side effects with improved therapeutic 
efficacy. Microsponge can be effectively incorporated 
into topical drug delivery system for retention of dosage 
form on skin, and also use for oral delivery of drugs 
using bio erodible polymers, especially for colon specific 
delivery and controlled release drug delivery system thus 
improving patient compliance by providing site specific 
drug delivery system and prolonging dosage intervals. 
This technology is being used currently in cosmetics, 
over-the-counter skin care, sunscreens, and prescription 
products. This kind of drug delivery technology may lead 
to a better understanding of the healing of several 
diseases. Hence, the microsponge-based drug delivery 
technology is likely to become a valuable drug delivery 
matrix substance for various therapeutic applications in 
the future. 
Ease manufacturing, simple ingredients and wide range 
actives can be entrapped along with a programmable 
release make microsponges extremely attractive. It is 
originally developed for topical delivery of drugs like 
anti-acne, anti-inflammatory, anti-fungal, anti-dandruffs, 
antipruritics, rubefacients etc. Microsponge Delivery 
System holds a promising future in various 
pharmaceutical applications in the coming years as they 
have unique properties like enhanced product 
performance and elegancy, extended release, reduced 
irritation, improved thermal, physical, and chemical 
stability so flexible to develop novel product forms. 
Researchers are continuously trying to develop a drug 
delivery system which is cost effective and having better 
therapeutic efficacy. The technology showed such 
promises to meet researchers expectations. numerous 
studies reveal that microsponge systems are non-
irritating, non-mutagenic, non-allergenic, and non-toxic. 
A Microsponge Delivery System can entrap wide range 
of actives and then release them onto the skin over a time 
and in response to trigger. It is a unique technology for 
the controlled release of topical agents and consists of 
microporous beads loaded with active agent and also use 
for oral as well as biopharmaceutical drug delivery. A 
Microsponge Delivery System can release its active 
ingredient on a time mode and also in response to other 
stimuli. Thus microsponge has got a lot of potential and 
is a very emerging field which is needed to be explored.  
 
 
REFERENCES: 
1. Nacht S and Kantz M. The Microsponges, A Novel Topical 
Programmable Delivery System. Chapter 15, In, Topical Drug 
Delivery System. Edited by David WO and Anfon HA, 42, 
1992, 299-325.  
2. Kirti Deshmukh, Sushilkumar S Poddar. Solid porous 
microsphere: emerging trend in pharmaceutical technology. Int 
J Pharm Bio Sci, 2(1), 2011, 364-377.  
3. Patel SB, Patel HJ and Seth AK. Microsponge drug delivery 
system: an overview. J Global Pharm Tech, 2(8), 2010, 1-9.  
4. Viral Shaha, Hitesh Jain, Jethva Krishna1, Pramit Patel. 
Microsponge drug delivery: A Review. Int. J. Res. Pharm. Sci, 
1(2), 2010, 212-218.  
5. Shivani Nanda, Mandeep Kaur, Nikhil Sood, Sahil Nagpal, 
Microsponge drug delivery system: an overview, World 
Journal of Pharmacy and Pharmaceutical Sciences, Volume 2, 
Issue 3, 1032-1043. 
6. Aity, S., et al., Microsponges: A novel strategy for drug delivery 
system. J Adv Pharm Technol Res, 2010. 1(3): p. 90-283. 
7. Chadawar, V. and J. Shaji, Microsponge delivery system. Curr 
Drug Deliv, 2007 4(2): 9-123. 
8. Namrata Jadhav, Vruti Patel, Siddhesh Mungekar, Manisha 
Karpe, Vilasrao Kadam, Microsponge delivery system: an 
updated review, current status and future prospects, World 
Journal of Pharmacy and Pharmaceutical Sciences, Volume 2, 
Issue 6, 6463-6485. 
9. Won R: Method for delivering an active ingredient by controlled 
time release utilizing a novel delivery vehicle which can be 
prepared by a process utilizing the active ingredients as a 
Porogen. 1987; US Patent No. 4690825. 
10. Patidar K, Soni M, Saxena C, Soni P, Sharma DK. 
Microspongea versatile vesicular approach for transdermal 
drug delivery system. J Global Pharm Tec, 2(3), 2010, 154-
164.  
11. N.H. Aloorkar, A.S. Kulkarni, D.J. Ingale and R.A. Patil, 
Microsponges as Innovative Drug Delivery Systems, 
International Journal of pharmaceutical Sciences and 
Nonotechnology, 5(1), 2012. 
12. D‟souza J.I., More H.N. Topical Anti-Inflammatory Gels of 
Fluocinolone Acetonide Entrapped in Eudragit Based 
Microsponge Delivery System. Res J Pharm Tech 1(4), 
2008,502-506. 
13. Hibah Aldawsari and Shaimaa M. Badr-Eldin, Microsponges as 
promising vehicle for drug delivery and targeting: Preparation, 
characterization and applications, African Journal of Pharmacy 
and Pharmacology, 3(1), 2001, 873-881. 
14. Aritomi H, Yamasaki Y, Yamada K, Honda H, Koshi M. 
Development of sustained release formulation of 
chlorpheniramine maleate using powder coated microsponges 
prepared by dry impact blending method. J. Pharm. 
Sci.Technol. 56(1), 1996, 49-56. 
15. Jain V, Singh R. Design and characterization of colon-specific 
drug delivery system containing paracetamol microsponges. 
Arch. Pharm. Res. 34, 2011, 733-740. 
16.Vyas SP, Khar RK. Targeted and controlled drug delivery: 
novel carrier systems. CBS Publications, 1st ed., New Delhi, 
453, 2002. 
17. Swetha, Gopal Rao, Venkata Ramana K, Niyaz Basha B and 
Koti Reddy V. Formulation and in-vitro evaluation of etodolac 
entrapped in microsponge based drug delivery system. Int J 
Pharma, 1(2), 2011, 73-80.  
18. Santanu Kaity, Sabyasachi Maiti, Ashoke Kumar 
Ghosh,Subham Banerjee. Microsponge: A novel strategy for 
drug delivery system. J. Adv. Pharma. Tech. Res, 1(3), 2010, 
283-290.  
Kapoor et al                                         Journal of Drug Delivery & Therapeutics; 2014, 4(5), 29-35 35 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
19. Panwar AS, Yadav CS, Yadav P, Darwhekar GN, Jain DK, 
Panwar MS, Agrawal A. Microsponge a novel carrier for 
cosmetics. JGPT, 3(7), 2011, 15-24.  
20. Vikrant K, Nikam, RT Dolas, Somwanshi SB, Gaware VM, 
Kotade KB, Dhamak KB, Khadse AN and Kashid VA. 
Microparticles: a novel approach to enhance the drug delivery - 
a review. IJPRD, 3(8), 2011, 170- 183.  
21. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman‟s 
„ThePharmacological Basis of Therapeutics‟. 11th Edition. 
2006, 1021. 
22. John I D' Souza and Harinath N. Topical anti-inflammatory 
gels of fluocinolone acetonide entrapped in eudragit based 
microsponge delivery system. Research J Pharm and Tech, 
1(4), 2008, 502.  
23. Comoglu T, Gonul N, Baykara T, Preparation and in vitro 
evaluation of modified release ketoprofen microsponges, II, 
Farmaco, 58, 2003, 101-106. 
24. Neelam Jain, Pramod Kumar Sharma, Arunabha Banik, Recent 
advances on microsponge delivery system, International 
Journal of Pharmaceutical Sciences Review and Research, 
Volume 8, Issue 2, May – June 2011. 
25. Khopade AJ, Jain S, Jain NK, The microsponge, Eastern 
Pharmacist, 1996, 49-53. 
26. Christensen MS, Natch SJ. Invest. Dermato. 1983;69:282. 
27. Vikrant K, Nikam, RT Dolas, Somwanshi SB, Gaware VM, 
Kotade KB, Dhamak KB, Khadse AN and Kashid VA. 
Microparticles: a novel approach to enhance the drug delivery - 
a review. IJPRD, 3(8), 2011, 170- 183.  
28. Madhu Sharma, Baibhav Joshi. Microsponges: A 
comprehensive Review. The Global J Pharm Res, 1(3), 2012, 
359-377.  
29. Saurabh Kumar, Tyagi LK, and Dashrath Singh. Microsponge 
delivery system (MDS): A unique technology for delivery of 
active ingredients. IJPSR, 2(12), 2011, 3069-3080.  
30. Patel EK and Oswal RJ. Nanosponge and micro sponges: A 
novel drug delivery system. Int J Res in Pharm and Chem, 
2(2), 2012, 237-244.  
31. Saroj Kumar Pradhan. Microsponges as the versatile tool for 
drug delivery system. IJRPC, 1(2), 2011, 243-258.  
32. Swetha, Gopal Rao, Venkata Ramana K, Niyaz Basha B and 
Koti Reddy V. Formulation and in-vitro evaluation of etodolac 
entrapped in microsponge based drug delivery system. Int J 
Pharma, 1(2), 2011, 73-80.  
33. Kawashima YNT, Takeuchi HH, Tomoaki IY. Control of 
Prolonged Drug Release and Compression Properties of 
Ibuprofen Microsponges with Acrylic Polymer, Eudragit RS, 
by Changing Their Intraparticle Porosity. Chemical & 
pharmaceutical bulletin, 40(1), 1992, 196-201.  
34. Patel EK and Oswal RJ. Nanosponge and Microsponges, a 
Navel Drug Delivery System. International Journal of 
Research in Pharmacy, 2(2), 2012, 238.  
35. Ramani Gade, Anitha Makineni, Aparna A, Krishna Keerthi B, 
TEGK Murthy, Chandu Babu Rao, Sreekant Nama. Design and 
development of Hydroxyzine hydrochloride controlled release 
tablets based on microsponges, Caribbean Journal of Science 
and Technology, 1, 2013, 172.  
36. Karthika R, Elango K, Ramesh Kumar K, Rahul K. 
Formulation and evaluation of lornoxicam microsponges 
tablets for the treatment of arthritis. International Journal of 
Pharmaceutical Innovations, 3(2), 2013, 29.  
37. Saboji JK, Manvi FV, Gadad AP and Patel BD. Formulation 
and evaluation of ketoconazole microsponges gel by quassi 
emulsion solvent diffusion. Journal of Cell and Tissue 
Research, 2(1), 2011, 26-31.  
38. Jangde R. Microsponges for colon targeted drug delivery 
system, An overview. Asian J Pharm Tech, 1(4), 2011, 89.  
39. Jain N, Kumar Pramod Sharma, Banik Arunabha. Recent 
advances on microsponges delivery system. International 
journal of Pharmaceutical Sciences Review and Research, 
8(2), 2011, 16.  
40. Jain V, Singh R. Dicyclomine-loaded Eudragit-based 
Microspongewith Potential for Colonic Delivery, Preparation 
and Characterization. Tropical Journal of Pharmaceutical 
Research, 9(1), 2010, 67-72.  
41. Bhumika Sharma, Arvind Sharma. Future prospect of 
nanotechnology in development of anti-ageing formulations. 
Int J Pharm Pharm Sci, 4(3), 2012, 57-66.  
42. Rekha U, Manjula BP. Formulation and evaluation of 
microsponges for topical drug delivery of mometasone furoate. 
Int J Pharm Pharm Sci, 3(4), 2010, 133-137.  
43. D‟souza JI, The Microsponge Drug Delivery System: For 
Delivering an Active Ingredient by Controlled Time Release. 
Pharma. info.net, 2008, 6 (3): 62. 
44. Sarat C. P. M., Ajay M., Nagendra B.B., Prathyusha P., 
Audinarayana N., Bhaskar R.K.Microsponge Drug Delivery 
System . A Review. J. Pharm. Res.2011; 4(5): 1381-1384. 
45. D‟souza JI. In-vitro Antibacterial and Skin Irritation Studies of 
Microsponges of Benzoyl Peroxide. Indian Drugs. 2001, 38(7): 
23. 
46. Wester R., Patel R., Natch S., Leyden J., Melendres J., Maibach 
H., Controlled release of benzoyl peroxide from aporous 
microsphere polymeric system can reduce topical irritancy, J. 
Am. Acad. Derm., 1991, 24, 720-726. 
47. John I. D'souza, Jagdish K. Saboji, Suresh G. Killedar, 
Harinath N. More “Design and Evaluation of Benzoyl Peroxide 
Microsponges to Enhance Therapeutic Efficacy in Acne 
Treatment”, Accepted for presentation in 20th FAPA Congress, 
Bangkok , Thailand , Nov Dec 3, 200428. 
48. Trotta F, Cavalli R, Tumiatti W. Cyclodextrin-based 
nanosponges for drugdelivery. J Inc Phenom Macro cyclic Chem. 
2006; 56:209-13. 
 
 
